|
Pursuing Parkinson's Disease Gene Therapies: Strategies & Operational Requirements, Upcoming Webinar Hosted by Xtalks
Tuesday, April 13, 2021
In this free webinar, the featured speakers from Premier Research will discuss alternate gene therapies such as opto- and chemogenetics and novel genome-editing technology as well as the use of engineered, non-replicating viral vectors, predominantly recombinant adeno-associated virus or lentivirus. Attendees will learn how to meet the requirements for surgical techniques and equipment when performing intra-CNS administration of viral vectors and operational considerations for Parkinson's disease gene therapy studies.
TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- While treatment of Parkinson's disease (PD) has traditionally been limited to dopamine replacement therapy to alleviate symptoms, gene therapy studies have recently evaluated both non-disease-modifying and disease-modifying transgenes for PD treatment, with encouraging results.
Non-disease-modifying therapies have improved symptomatology and disease-modifying strategies, including stopping PD-mediated cell death and/or regenerating lost neurons, and show potential in slowing disease progression. However, these studies face unique challenges due to their patient population and the complex regulatory considerations for these advanced therapies.
Conducting these trials requires careful attention to investigator and site selection and adherence to local regulatory and protocol design requirements. The need for long-term patient follow-up, potentially as long as 15 years, puts added demands on patients and sites.
Join expert speakers from Premier Research, Andreas Schreiner, M.D., Vice President, Medical Affairs Neuroscience and Analgesia; and Hanna Wide, M.S., Executive Director, Cell and Gene Therapy, in a live webinar on Wednesday, April 14, 2021 at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Pursuing Parkinson's Disease Gene Therapies: Strategies & Operational Requirements.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Sydney Perelmutter
Tel: +1 (416) 977-6555 x 352
Email: sperelmutter@xtalks.com
Media Contact
Sydney Perelmutter, Xtalks, (416) 977-6555 x352, sperelmutter@xtalks.com
SOURCE Xtalks
|
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026
|
|
StackGen Named in Four Gartner® Hype Cycles(TM) for Platform Engineering, Infrastructure Strategy, Site Reliability Engineering, and I&O Automation in 2025 | Jan 22, 2026
|
|
|
|
